ClinicalTrials.gg
RecruitingNCT06940713CONEXUSUpdated Dec 18, 2025

Prospective Study of the Feasibility of Brain Connectivity Imaging by Functional Ultrasound Imaging (fUS) in Newborn Infant

An interventional study of Imaging Time in Neonates and Preterm Infants and Neonates or Premature Babies, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged Up to 5 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
Up to 5 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.

Planned enrollment
64th of 104
76 · median 98
Started
2025
with 10 others
No phase
80 of 205
17 open now
Primary completion
2030-04
later than 41 of 45 live
Registered
191st of 205
by date

Among the 205 studies in Premature Birth with a site in France, this one is the 64th largest by planned enrollment of the 104 interventional ones that give a count, is one of 11 that started in 2025, is one of 80 with no phase, reaches primary completion later than 41 of the 45 other live ones, and was the 191st registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 5 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Premature Birth with a site in France, or all of them as a file.
02

Study summary

Neurodevelopmental disorders (NDD) affect how the brain develops and can lead to lifelong difficulties with movement, learning, behavior, and thinking. Every year, around one million newborns in Europe are affected by these conditions. Some babies are at higher risk of NDD due to factors such as being born extremely premature, having poor growth in the womb, experiencing a lack of oxygen at birth, or having a family history of severe NDD. However, predicting which babies will develop these disorders is currently very challenging because there are no reliable early indicators (biomarkers) to detect them.

The CONEXUS study is testing a new type of brain imaging technology called functional ultrasound imaging (fUS) to see if it can help assess brain function in newborns at high risk of NDD. This technique measures brain activity by detecting small changes in blood flow, similar to an ultrasound scan but using advanced imaging technology. Researchers believe this method, known as fC-fUS imaging, could help identify early signs of neurodevelopmental disorders.

Preliminary studies have shown that fUS imaging can detect brain activity changes in newborns, such as differences between sleep states or during epileptic seizures. The CONEXUS study will expand on this by improving the imaging technology and testing it in a larger group of newborns, including those born prematurely, those with restricted growth, those who needed cooling treatment after birth due to lack of oxygen, and those at risk for autism spectrum disorder (ASD).

The study is being conducted in multiple hospitals in France over five years, involving newborn intensive care, pediatrics, and child psychiatry teams. It is a feasibility study, meaning researchers aim to test whether this imaging technique is practical and effective for use in newborns. Babies will have short, painless fUS scans that focus on brain regions involved in movement, hearing, vision, and attention.

Ultimately, the goal of CONEXUS is to demonstrate that fC-fUS imaging can help doctors understand early brain development and identify signs of neurodevelopmental disorders before symptoms appear. If successful, this technique could improve early diagnosis, allowing doctors to start treatment sooner and improve long-term outcomes for affected children. This research has the potential to transform neonatal care by providing a new tool for detecting and monitoring brain function in newborns.

Read the detailed description

Introduction

Neurodevelopmental disorders (NDD) result from an alteration in brain development and represent a major public health problem, affecting 1 million newborns in Europe each year. Neurodevelopmental disorders are the source of permanent disabilities that manifest as motor, cognitive, learning, or behavioral dysfunction. Prenatal or neonatal factors considered high risk for NDD include: extreme prematurity, newborns with intrauterine growth retardation, brain growth abnormalities, anoxic-ischemic encephalopathy (AIE) with an indication for therapeutic hypothermia, and a family history of severe NDD in the first degree. Establishing a reliable prognosis for neurodevelopmental disorders is extremely difficult because there are currently no early biomarkers to detect and assess potential long-term deficiencies.

The CONEXUS protocol aims to evaluate whether a unique neuroimager, using ultrafast ultrasound imaging, is capable of assessing, at the patient's bedside, the brain's functional connectivity (fC) in newborns at high risk of NDD. This neuroimager uses functional ultrasound imaging (fUS), a technique developed within the Physics for Medicine laboratory (Paris), and thus constitutes the central medical device of this protocol.

Device

The CONEXUS system is composed of several elements necessary for functional brain imaging of newborns: the Conexus station (similar to an ultrasound machine) on which the Conexus software is installed (allowing the acquisition and processing of ultrasound data necessary for imaging), the ultrasound probe (a physical element allowing the emission and reception of ultrasounds, similar to an ultrasound probe), and the headset (a small system adapted to the anatomy of the patient's head and allowing the probe to be held in place over the fontanelle).

This system allows mapping of brain activity via subtle changes in cerebral blood volume. It is quite similar to an ultrasound machine but uses different image reconstruction and signal processing techniques, which give it its properties. Our research hypothesis: the evaluation of fC by fUS imaging (fC-fUS imaging) is feasible in newborns and could eventually reveal early biomarkers of perinatal brain diseases.

This hypothesis is supported by our preliminary work on neonatal fUS imaging: we have shown the possibility of performing fUS imaging in some newborns and thus measuring a change in brain activity during sleep state changes or during epileptic seizures, as well as at different stages of neurodevelopment (premature vs. term). The CONEXUS study aims to go further thanks to improved technical capabilities and ergonomics (notably the ultrasound probe) allowing multiplane imaging approaching 3D imaging and imaging a large clinical cohort including different stages of development and various pathological risks (term newborns, premature newborns, newborns with intrauterine growth retardation (IUGR), AIE newborns placed in therapeutic hypothermia, and newborns at risk of autism spectrum disorder (ASD)).

Study

Conexus is a descriptive research study of neonatal brain connectivity using fUS imaging. It is a national clinical investigation involving the Neonatal Intensive Care and Pediatrics/Maternity and Child Psychiatry Services of the Robert Debré Hospital, and concerning a medical device (MD), classified as IIa non-CE marked, without the objective of establishing CE marking (IC 4.4). It therefore uses a new medical device for research purposes, the "Conexus" system, which is a joint production of the Physics for Medicine Paris laboratory and the Iconeus company carried out under a scientific collaboration contract. It is a prospective feasibility pilot study, multicentric, open, controlled, and non-randomized. The research will last 5 years, including 3 years of inclusion.

The fUS examinations consist of recording brain activity for a few minutes in one of the imaging planes (Posterior Coronal, Median Coronal, Frontal Coronal, Right Para-sagittal, Right/Left Para-sagittal, 3-plane Antero-posterior Coronal) including structures involved in brain functional connectivity networks (somatosensory, auditory, visual, salience). These fUS examinations are conducted to perform longitudinal follow-up of patients in the different groups.

CONEXUS aims to prove the potential of fC-fUS to characterize and monitor brain functions, understand the developing brain, and search for biomarkers of neurological deficiencies. The definition of early biomarkers of neurodevelopmental disorders would allow early management to guide therapeutic decisions and improve treatment effects. fUS imaging and fC-fUS evaluation have the potential to transform the clinical management of newborns and address a pressing clinical need in neonatology.

Objectives

Main objective: To evaluate the feasibility of acquiring data via fUS imaging of brain functional connectivity in 4 groups (G1 to G4) of newborns at high risk of NDD and a control group of term newborns (G5): group G1 of premature newborns born before 32 weeks of amenorrhea (WA) (N = 26), group G2 of newborns with anoxic-ischemic neonatal encephalopathy >36 WA (AIE) (N = 10), group G3 of newborns with IUGR \<10th percentile (N = 10), group G4 of newborns from siblings with autism spectrum disorder (ASD) (N = 10), compared to a control group (G5) of term newborns without neurological pathology (N = 20).

Secondary objectives:

  • To study the evolution of fUS connectivity in premature infants (G1), from birth to corrected term in relation to brain functional connectivity in term newborns (G5), newborns with anoxic-ischemic encephalopathy (AIE) (treated with therapeutic hypothermia) (G2), newborns with IUGR (G3), and newborns from siblings with at least one child with autism spectrum disorder (ASD) (G4).
  • To identify a posteriori within the groups of premature infants (group G1), newborns with AIE (group G2), newborns with IUGR (group G3), and newborns from siblings with ASD (group G4), any early markers of an abnormal neurodevelopmental trajectory (identified based on neuropsychological evaluation at 2 years).
  • To create 3D vascular atlases specific to fUS imaging to document the evolution of cerebrovascular structures (vessels >100µm) in premature infants (group G1), newborns with AIE (G2), newborns with IUGR (G3), and term newborns (group G5), as these data are currently non-existent.
  • To create for the first time simultaneous clinical fUS-EEG recordings to study their possible correlations for the 5 groups. By studying possible correlations, we mean, for example, the study of the possible difference in the nature of fUS signals during clearly identified EEG activity periods (e.g., sleep phases).
03

Conditions studied

  • Neonates and Preterm Infants
  • Neonates or Premature Babies

Keywords

  • ultrasound imaging
  • functional ultrasound
  • neonatal intensive care imaging
  • prematurity
  • preterm
  • anoxo-ischemic encephalopathy
  • intrauterine growth restriction
  • functional connectivity
  • neonatology
  • neurodevelopment
04

Who can participate

Ages eligible
Up to 5 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. For group G1 (Premature babies):

Gestational children:

1a. Between 23 WA+5 days and 27 WA +6 days (extremely preterm) (G1) or

1b. Between 28 WA+0 days and 31 WA+6 days (very preterm) (G1)

2. For the G2 group (AIE):

  • Children of gestational age> 36 WA + 0 days
  • with neonatal anoxo-ischemic encephalopathy
  • treated with controlled therapeutic hypothermia (group G2)

    3. For the G3 Group (IUGR): Gestational age between 32 WA+0 days and 40 WA+6 days and with IUGR intrauterine growth restriction: birth weight \< 10 p and/or head circumference \< 10 percentile (G3 group);

    4. For the G4 group :

  • Siblings with at least one child with signs of autism spectrum disorder
  • less than 6 months of age at baseline (G4 group)

    5. For the G5 group (control):

  • Children of gestational age between 39 WA and 40 WA + 6 days
  • without pathology during pregnancy (no vasculoplacental pathology, no threat of premature delivery, no maternal therapy, no consumption of toxic substances)
  • at birth: Apgar greater than 6 at M10; pH>7.20; lactate\< 6 mmol/l; eutrophic; Birth weight >10p; Cranial Perimeter >10p

    6. Consent of the holders of parental authority 7. Child affiliated to or in receipt of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Person subject to a judicial safeguard measure (guardianship, curatorship or safeguard of justice)
  • Known malformative pathology;
  • Known chromosomal abnormality;
  • Known allergy to silicone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Feasibility of brain connectivity imaging by functional ultrasound imaging (fUS) in newborn infant

    Device: Imaging Time

Interventions

  • DeviceImaging Time

    fUS: transfontanellar functional ultrasound imaging, performed using the CONEXUS system. fUS-EEG: transfontanellar functional ultrasound imaging, performed using the CONEXUS system, performed simultaneously with an EEG examination. The fUS examinations consist of recording brain activity for a few minutes in one of the imaging planes (Posterior Coronal, Median Coronal, Frontal Coronal, Right Para-sagittal, Right/Left Para-sagittal, 3-plane Antero-posterior Coronal) including structures involved in brain functional connectivity networks (somatosensory, auditory, visual, salience). These fUS examinations are conducted to perform longitudinal follow-up of patients in the 5 different groups.

    Also known as: functional ultrasound imaging (fUS), fUS, functional ultrasound imaging combined with EEG (fUS-EEG), fUS-EEG, CONEXUS imaging

06

What researchers measure

Primary outcomes

  1. Feasibility of acquiring quantitative brain functional connectivity assessment using fUS data in 4 groups (G1 to G4) of newborns at high risk of neurodevelopmental disorder and a control group of term newborns.

    Each fUS acquisition, for each patient, each acquisition time point, each imaging plane, consists of a succession of fUS images recorded over a duration ranging from 5 to 10 minutes. The acquisition will be considered successful if at least 50% of the fUS images do not show motion artifacts (criterion used in our preliminary studies) (validity criterion) and if vascular structures are visible at a depth \>50% of the maximum depth (sensitivity criterion). If these two criteria are met, we can then average the fUS signal over the functional areas and calculate a correlation matrix.

    Time frame: up to 16 weeks

Secondary outcomes

  1. Feasibility of longitudinal quantification of fUS connectivity of preterm (from birth to equivalent term age) and term newborns in different connectivity networks

    Static connectivity matrices are calculated for specific imaging planes via signals averaged over predefined functional areas (including: thalamus, precentral gyrus, postcentral gyrus, temporal lobe, Heschl's gyrus, insula, anterior and posterior cingulate cortex, frontal lobe, striatum, amygdala, visual cortex V1 V2) within an fUS acquisition. These matrices are compared after Fisher transformation via an ANOVA (Analysis of variance) and post hoc student test with correction (significance levels 95%)

    Time frame: up to 16 weeks

  2. Potential correlation between fUS connectivity assessment and neuropsychological assessment at 2 years within the groups of newborns at high risk of neurodevelopmental disorder

    Quantitative connectivity assessment of the preterm newborn group will be compared to the Brunet-Lézine neurodevelopmental score at 2 years, to identify a potential correlation.

    Time frame: 2 years

  3. Feasibility of acquisition of 3D vascular atlases specific to fUS imaging in order to document the evolution of cerebrovascular structures in newborns at high risk of neurodevelopmental disorder and term newborns

    No statistical analysis and no quantitative metrics, the measurement is of documentary value.

    Time frame: up to 16 weeks

  4. Quantify potential correlates between fUS and EEG data thanks to the simultaneous fUS-EEG clinical recordings in newborns at high risk of neurodevelopmental disorder and term newborns.

    Comparison of connectivity between different sleep phases. The occurrences of different connectivity states will be evaluated for each group in the two sleep phases and tested via an ANOVA and post hoc Tukey's test, as for secondary outcome measure 2.

    Time frame: up to 16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2030, 53 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 53 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Apr 23, 2025
StartActual
Nov 28, 2025
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2030
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06940713
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Nov 28, 2025
Primary completion
Apr 2030 (estimated)
Completion
Apr 2030 (estimated)
Last update
Dec 18, 2025

Study contacts

Valerie BIRAN, MD
Contact
valerie.biran@aphp.fr
+33 1 40 03 41 91
Valerie BIRAN, MD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion